| Not Yet Recruiting | A Study of TAK-505 in Adults With Solid Tumors NCT07436728 | Takeda | Phase 1 / Phase 2 |
| Not Yet Recruiting | One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid NCT06781125 | Immorna Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors NCT07268040 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 |
| Not Yet Recruiting | A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors NCT07229612 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting NCT07124195 | The First Affiliated Hospital of Xinxiang Medical College | Phase 3 |
| Recruiting | A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors NCT07028281 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 |
| Recruiting | Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia NCT06629584 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors NCT06737731 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | The Effect of Serum Ferritin in irAE NCT06702566 | Tianjin Medical University Cancer Institute and Hospital | N/A |
| Unknown | A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumo NCT06082557 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Completed | Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors NCT05930457 | The First Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Recruiting | Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of NCT05579275 | Peking University Cancer Hospital & Institute | EARLY_Phase 1 |
| Completed | First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors NCT05814835 | Chinese PLA General Hospital | Phase 1 |
| Completed | An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are NCT05594147 | Bayer | — |
| Unknown | A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors NCT05508620 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| Unknown | Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors NCT05441046 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors NCT03739827 | National Cancer Institute (NCI) | — |
| Completed | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas NCT03205176 | AstraZeneca | Phase 1 |
| Completed | tTF-NGR Phase I Study NCT02902237 | University Hospital Muenster | Phase 1 |
| Recruiting | Characterization of Hyperpolarized Pyruvate MRI Reproducibility NCT02421380 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy NCT02805166 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Phase 4 |
| Unknown | Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors NCT01694472 | Tianjin Medical University Cancer Institute and Hospital | Phase 1 |
| Completed | Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors NCT01765790 | Baxalta now part of Shire | Phase 1 |
| Completed | Cancer Vaccine Targeting Brachyury Protein in Tumors NCT01519817 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Mali NCT01391533 | Sanofi | Phase 1 |
| Completed | Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan NCT00516438 | AstraZeneca | Phase 1 |
| Recruiting | Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research NCT05539677 | N.N. Petrov National Medical Research Center of Oncology | — |